There is currently no text in this page. You can search for this page title in other pages, or search the related logs, but you do not have permission to create this page.
Category:Regeneron Pharmaceuticals, Inc.
Subcategories
This category has the following 44 subcategories, out of 44 total.
A
B
D
E
G
H
J
K
L
M
N
P
R
S
T
V
W
X
Y
Pages in category "Regeneron Pharmaceuticals, Inc."
The following 84 pages are in this category, out of 84 total.
1
- 17415589. Compositions and Methods for Enhancing Body Weight and Lean Muscle Mass Using Antagonists Against Leptin Receptor, GDF8 and Activin A simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18400943. RADIOLABELED MET BINDING PROTEINS FOR IMMUNO-PET IMAGING simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18412280. FGFR3 BINDING MOLECULES AND METHODS OF USE THEREOF simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18420090. SYSTEMS AND METHODS FOR MOBILE AND STATIC BIOMETRIC MOVEMENT TRACKING simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18420955. METHODS OF MODELING LIQUID PROTEIN COMPOSITION STABILITY simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18421326. Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18422188. MASS SPECTROMETRY-BASED CHARACTERIZATION OF ANTIBODIES CO-EXPRESSED IN VIVO simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18438746. METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18442444. Non-Human Animals Expressing Humanized CD3 Complex simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18588774. ACE2-IgM-Fc FUSION PROTEINS AND USES THEREOF simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18589384. MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18597797. ADAM6 MICE simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18603862. SYSTEMS AND METHODS FOR IDENTIFYING EVENTS IN SUPPLY CHAIN PROCESSES simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18606302. Proteomic Risk Score For Osteoarthritis (OA) simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18608561. METHODS AND COMPOSITIONS FOR SENSITIZATION OF TUMOR CELLS TO IMMUNE THERAPY simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18637124. ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18672959. TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18672979. TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18680910. ANTI-NPR1 ANTIBODIES AND USES THEREOF simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18704681. CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR KNOCKING OUT C5 (Regeneron Pharmaceuticals, Inc.)
- 18737782. Anti-Trkb Monoclonal Antibodies And Methods Of Use simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 18742805. SYSTEMS, DEVICES, AND METHODS OF A DATA PIPELINE (Regeneron Pharmaceuticals, Inc.)
- 18744010. AUTO-INJECTOR AND RELATED METHODS OF USE (Regeneron Pharmaceuticals, Inc.)
- 18744094. MEDICAL DEVICE PACKAGING AND RELATED METHODS (Regeneron Pharmaceuticals, Inc.)
- 18744415. VECTORS, GENETICALLY MODIFIED CELLS, AND GENETICALLY MODIFIED NON-HUMAN ANIMALS COMPRISING THE SAME (Regeneron Pharmaceuticals, Inc.)
- 18745346. HOST CELL PROTEIN ANALYSIS FOR ADENO-ASSOCIATED VIRUS (AAV)-BASED GENE THERAPY (Regeneron Pharmaceuticals, Inc.)
- 18757848. PROCESS FOR REDUCING SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION (Regeneron Pharmaceuticals, Inc.)
- 18817721. Treatment Of Liver Disease Or Metabolic Disorder With Folliculin Interacting Protein 1 (FNIP1) Inhibitors And/Or Folliculin (FLCN) Inhibitors (Regeneron Pharmaceuticals, Inc.)
- 18835452. GJB2 REGULATORY ELEMENTS AND USES THEREOF (Regeneron Pharmaceuticals, Inc.)
- 18911994. Treatment Of Macular Degeneration With Complement Factor D (CFD) Inhibitors (Regeneron Pharmaceuticals, Inc.)
- 18918283. RAPID PURIFICATION OF MONOCLONAL ANTIBODY FROM IN-PROCESS UPSTREAM CELL CULTURE MATERIAL (Regeneron Pharmaceuticals, Inc.)
- 18925530. Treatment Of Osteoarthritis With Procollagen Galactosyl Transferase 2 (COLGALT2) Inhibitors (Regeneron Pharmaceuticals, Inc.)
- 18984162. CRISPR/CAS SCREENING PLATFORM TO IDENTIFY GENETIC MODIFIERS OF TAU SEEDING OR AGGREGATION (Regeneron Pharmaceuticals, Inc.)
- 19000899. DEVICES AND METHODS FOR PRECISION DOSE DELIVERY (Regeneron Pharmaceuticals, Inc.)
2
- 20240009674. SUPPORT FOR TEST DEVICE simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 20240018467. TAURINE SUPPLEMENTED CELL CULTURE MEDIUM AND METHODS OF USE simplified abstract (Regeneron Pharmaceuticals, Inc.)
- 20250152643. Combinations O (Regeneron Pharmaceuticals, .)
- 20250152643. Combinations O (Regeneron Pharmaceuticals, Inc.)
- 20250152669. Use Of A Vegf (Regeneron Pharmaceuticals, Inc.)
- 20250152669. Use Vegf (Regeneron Pharmaceuticals, .)
- 20250152818. Auto-injector (Regeneron Pharmaceuticals, .)
- 20250152818. Auto-injector (Regeneron Pharmaceuticals, Inc.)
- 20250152832. Devices And Me (Regeneron Pharmaceuticals, Inc.)
- 20250152832. Devices Me (Regeneron Pharmaceuticals, .)
- 20250153429. Systems And Me (Regeneron Pharmaceuticals, Inc.)
- 20250153429. Systems Me (Regeneron Pharmaceuticals, .)
- 20250154267. Methods For Tr (Regeneron Pharmaceuticals, Inc.)
- 20250161457. Process Re (Regeneron Pharmaceuticals, .)
- 20250161476. Antibody-drug (Regeneron Pharmaceuticals, .)
- 20250162260. Systems Me (Regeneron Pharmaceuticals, .)
- 20250163134. Hydrophobic (Regeneron Pharmaceuticals, .)
- 20250163357. Capacitance Pr (Regeneron Pharmaceuticals, .)
- 20250163468. Covalently Sur (Regeneron Pharmaceuticals, .)
- 20250164488. Structure (Regeneron Pharmaceuticals, .)
- 20250164500. Protein Chro (Regeneron Pharmaceuticals, .)
- 20250164501. Biochemical As (Regeneron Pharmaceuticals, .)
- 20250170226. Methods Tre (Regeneron Pharmaceuticals, .)
- 20250171516. Peptide Acids (Regeneron Pharmaceuticals, .)
- 20250171520. Compositions (Regeneron Pharmaceuticals, .)
- 20250171545. N-terminal Scf (Regeneron Pharmaceuticals, .)
- 20250171622. Bis-octahydrop (Regeneron Pharmaceuticals, .)
- 20250179137. Il18 Receptor (Regeneron Pharmaceuticals, .)
- 20250179177. Stable Antibod (Regeneron Pharmaceuticals, .)
- 20250179469. Cblb Endonucle (Regeneron Pharmaceuticals, .)
- 20250188433. Compositions (Regeneron Pharmaceuticals, .)
- 20250188473. Methods Tre (Regeneron Pharmaceuticals, .)
- 20250194571. Compositions (Regeneron Pharmaceuticals, .)
- 20250206803. Methods Cha (Regeneron Pharmaceuticals, .)
- 20250206829. High Affinity (Regeneron Pharmaceuticals, .)
- 20250214062. Systems Me (Regeneron Pharmaceuticals, .)
- 20250216304. Universal Modu (Regeneron Pharmaceuticals, .)
- 20250218540. Immunotherapy (Regeneron Pharmaceuticals, .)
- 20250231141. Vegf-trap Prot (Regeneron Pharmaceuticals, .)
- 20250231191. Lc-ms Methods (Regeneron Pharmaceuticals, .)
B
R
- Regeneron Pharmaceuticals, Inc. (20250152643). COMBINATIONS OF CHECKPOINT INHIBITORS AND ONCOLYTIC VIRUS FOR TREATING CANCER
- Regeneron Pharmaceuticals, Inc. (20250152669). Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders
- Regeneron Pharmaceuticals, Inc. (20250152818). AUTO-INJECTOR AND RELATED METHODS OF USE
- Regeneron Pharmaceuticals, Inc. (20250152832). DEVICES AND METHODS FOR PRECISION DOSE DELIVERY
- Regeneron Pharmaceuticals, Inc. Patent Application Trends in 2024